Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
about
Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney functionAmphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropeniaAntifungal therapy in infants and children with proven, probable or suspected invasive fungal infectionsAntifungal therapy in infants and children with proven, probable or suspected invasive fungal infectionsPopulation pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseasesRecent advances in the management of mucormycosis: from bench to bedsideRecommendations for the Treatment of Invasive Fungal Infections in Hematological Malignancies: A Critical Review of Evidence and Turkish Expert Opinion (TEO-1)Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: A SEER database analysisAntifungal Therapy in Hematopoietic Stem Cell Transplant RecipientsLiposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)Efficacy of TAK-457, a novel intravenous triazole, against invasive pulmonary Aspergillosis in neutropenic mice.Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trialEfficacy and safety of amphotericin B lipid-based formulations-A systematic review and meta-analysis.Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia.Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group.Practice guidelines for lipid-based amphotericin B in stem cell transplant recipients.Mortality and costs of acute renal failure associated with amphotericin B therapy.Pharmacological advances in the treatment of invasive candidiasis.Invasive fungal infections in neutropenic enterocolitis: a systematic analysis of pathogens, incidence, treatment and mortality in adult patients.Fungal infection-related mortality versus total mortality as an outcome in trials of antifungal agents.Fluconazole for empiric antifungal therapy in cancer patients with fever and neutropeniaAntifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study.Pre-medication practices and incidence of infusion-related reactions in patients receiving AMPHOTEC: data from the Patient Registry of Amphotericin B Cholesteryl Sulfate Complex for Injection Clinical Tolerability (PRoACT) registry.Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B.Hematological toxicities associated with amphotericin B formulations.Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of AmerAntiinfectives update: focus on treatment and prevention of viral and associated infections.Weekly high-dose liposomal amphotericin B (L-AmB) in critically ill septic patients with multiple Candida colonization: The AmBiDex study.Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin BHypokalaemia-induced rhabdomyolysis after treatment of post-Kala-azar dermal Leishmaniasis (PKDL) with high-dose AmBisome in Bangladesh-a case report.Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1).Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection.Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America.A persistent challenge: the diagnosis of respiratory disease in the non-AIDS immunocompromised hostVoriconazole: the newest triazole antifungal agentPulmonary infection caused by Gymnascella hyalinospora in a patient with acute myelogenous leukemia.Safety and efficacy of multilamellar liposomal nystatin against disseminated candidiasis in persistently neutropenic rabbits.Efficacy of liposomal amphotericin B with prolonged circulation in blood in treatment of severe pulmonary aspergillosis in leukopenic rats.Single-dose AmBisome (Liposomal amphotericin B) as prophylaxis for murine systemic candidiasis and histoplasmosisSafety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study.
P2860
Q24187699-8E47A2B2-275B-4F7C-8DAA-877765750330Q24193811-29A813EC-95DE-437F-9741-CBE74B42BFCFQ24239978-FF5FAC00-E915-42CE-9B42-C4828F69CA46Q24243629-931CEE98-6954-442A-8DD6-4D557F90DBB5Q24542404-C1AE83D7-CC88-4D01-A5D2-A2370EECD867Q24642450-78CCB729-3FF4-4CFA-B873-D2A72B540668Q26824260-06153869-AF33-4838-956E-71F4ED21285FQ27336142-CEF5C12B-4707-4EC8-9145-41AAA1559182Q28080147-C042E290-13B9-48A6-94E8-427B61D0CC43Q28298468-E77E2A15-3333-4305-92EC-A58BD5CABC93Q28345150-89E97424-D48C-4C25-8A90-C93E6B28A6C6Q28359772-F7E23C2A-DEC1-4A9B-9127-F359A9C1E358Q30240770-476C4705-C7CC-4E89-A271-22D5CCFFBB0DQ30887348-46645312-9F3E-443C-8213-CBA3D1E488FBQ31372000-D3327C44-0AA0-49C0-B187-A2345878F5E1Q32052950-5ACDC813-685E-43E3-A6D0-9B4BBDB9E952Q32068576-34EB3A58-971B-4037-8185-A64D8E1335D8Q33232599-4BB9EE8C-DD33-4A2C-8BBA-1B3E56577503Q33234912-6A2AA5FE-95CE-4B87-9008-519D61B4EF51Q33253851-C1B86F0A-BACF-4F0A-8044-AC93BD4A7E1AQ33265510-BAC40FBA-D104-4FEB-976D-9313DA380370Q33289645-57AF35D9-5084-45D7-88FA-1AA735C57AF5Q33371455-25106F9D-CB80-4F0B-BCE9-DACA68B659A6Q33409652-F2EB3812-0105-432F-8766-06E989EACEB7Q33420040-75FF1BA2-E5CF-4680-BA47-C3DEEBD98679Q33650105-AE866AA0-362D-46B0-BBD1-2175A516CAEDQ33659379-01E9EBFA-58ED-44AB-B9FD-F878BDE09806Q33712955-2A3C1055-255E-405A-96DE-5044A3375490Q33722067-5663C5FA-A45B-4638-B53E-56AC9C585451Q33748160-CE9D1219-EC83-46F4-9648-89CB8226AAC4Q33753500-B2CEEB31-D2F9-44E6-8D06-CCFD35525656Q33876645-FCCC5AA7-17ED-42F6-BF7D-5D4C6B4FD67FQ33894467-C7CB7672-D84A-4F21-BAE7-BC21A37011EFQ33922242-D3A1BB87-22EA-4701-BD57-987182B957F1Q33946021-101F7AAF-DFC1-4A30-B54C-E212EAC274CCQ33974908-63B11BC0-09E9-4ED2-AC96-C79D27133A45Q33977852-878D2CA4-B502-49AC-8634-1529073F44CBQ33978902-5DB3D3B1-987F-4B4C-A0A2-751F5B1004CDQ33980413-253F9164-53A4-4984-89D4-2179E4A3521DQ33983629-DC729694-249A-4326-A3A7-A0B44A674ED2
P2860
Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
description
1999 nî lūn-bûn
@nan
1999 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մարտին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Liposomal amphotericin B for e ...... Diseases Mycoses Study Group.
@ast
Liposomal amphotericin B for e ...... Diseases Mycoses Study Group.
@en
type
label
Liposomal amphotericin B for e ...... Diseases Mycoses Study Group.
@ast
Liposomal amphotericin B for e ...... Diseases Mycoses Study Group.
@en
prefLabel
Liposomal amphotericin B for e ...... Diseases Mycoses Study Group.
@ast
Liposomal amphotericin B for e ...... Diseases Mycoses Study Group.
@en
P2093
P1476
Liposomal amphotericin B for e ...... Diseases Mycoses Study Group.
@en
P2093
Bodensteiner D
Finberg RW
Greenberg RN
Holcenberg JS
Schuster M
Schwartz C
P304
P356
10.1056/NEJM199903113401004
P407
P577
1999-03-01T00:00:00Z